Menu
Menu
Granules India has achieved a significant milestone with USFDA approval for its generic Lisdexamfetamine Dimesylate chewable tablets, providing a more affordable option for treating ADHD and binge eating disorder. This approval addresses critical drug shortages in the U.S. and strengthens Granules’ presence in the global pharmaceutical market.